Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to Buy at Wall Street Zen

Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

Other analysts have also issued research reports about the stock. Piper Sandler raised their target price on shares of Neurocrine Biosciences from $207.00 to $210.00 and gave the company an “overweight” rating in a research report on Friday. Weiss Ratings upgraded shares of Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, July 28th. Sanford C. Bernstein initiated coverage on Neurocrine Biosciences in a research note on Friday, May 22nd. They issued an “outperform” rating and a $221.00 price target for the company. Leerink Partners increased their price target on Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Finally, Stifel Nicolaus raised their price objective on Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.64.

Neurocrine Biosciences Stock Performance

NBIX opened at $166.80 on Friday. The company has a market cap of $16.77 billion, a P/E ratio of 24.46, a PEG ratio of 0.70 and a beta of 0.39. The company’s 50 day moving average is $167.81 and its 200-day moving average is $146.50. Neurocrine Biosciences has a 1-year low of $122.14 and a 1-year high of $186.12.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $179.60, for a total transaction of $1,796,000.00. Following the sale, the insider directly owned 54,729 shares of the company’s stock, valued at $9,829,328.40. The trade was a 15.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ingrid Delaet sold 4,367 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $181.02, for a total transaction of $790,514.34. Following the completion of the transaction, the insider owned 16,225 shares of the company’s stock, valued at approximately $2,937,049.50. This trade represents a 21.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 395,422 shares of company stock valued at $62,448,693 in the last quarter. 4.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Neurocrine Biosciences

Several institutional investors have recently modified their holdings of the business. Generali Investments Management Co LLC raised its position in Neurocrine Biosciences by 19.8% during the 2nd quarter. Generali Investments Management Co LLC now owns 10,644 shares of the company’s stock worth $1,794,000 after purchasing an additional 1,762 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in Neurocrine Biosciences by 9.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 205,871 shares of the company’s stock worth $34,696,000 after buying an additional 18,004 shares during the period. Fulton Bank N.A. lifted its holdings in Neurocrine Biosciences by 5.2% during the 2nd quarter. Fulton Bank N.A. now owns 4,895 shares of the company’s stock worth $825,000 after buying an additional 243 shares during the period. Valeo Financial Advisors LLC bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at about $283,000. Finally, Trust Point Inc. bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at about $245,000. Institutional investors own 92.59% of the company’s stock.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong Q2 performance: Second-quarter revenue rose 39% year over year to $959 million, exceeding the approximately $891 million analyst estimate. Adjusted earnings were $2.85 per share versus the $2.26 consensus, while net income increased to $144.4 million. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: Product and pipeline growth: INGREZZA sales increased 15% to $716 million, while CRENESSITY generated $184 million and newly acquired VYKAT XR contributed $54 million. Neurocrine also raised its 2026 INGREZZA sales guidance to $2.825 billion-$2.875 billion, supporting the company’s commercial outlook and Soleno Therapeutics acquisition. NBIX Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support strengthened: TD Cowen, Guggenheim, Stifel, Cantor Fitzgerald, Piper Sandler, Needham, RBC and Morgan Stanley all raised their price targets, with targets ranging from $196 to $222. William Blair also reiterated a Buy rating, citing strong execution and substantial pipeline potential. Analyst Price Target Updates
• Neutral Sentiment: Investor expectations remain elevated: Although NBIX beat quarterly estimates, the market appears to have wanted a larger revenue upside surprise or more aggressive full-year guidance. The reaction suggests investors may be reassessing how much near-term upside is already reflected in the shares.
• Negative Sentiment: Insider selling adds a cautionary signal: Director Leslie Norwalk sold 1,250 shares for about $228,000 under a pre-arranged Rule 10b5-1 plan. Broader data also show numerous insider sales and no open-market purchases over the past six months, though such transactions may be planned and do not necessarily indicate deteriorating fundamentals. SEC Insider Trading Filing

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.